Aptus Capital Advisors LLC Acquires 5,180 Shares of Eli Lilly and Company (NYSE:LLY)

Aptus Capital Advisors LLC lifted its position in Eli Lilly and Company (NYSE:LLY) by 17.1% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 35,477 shares of the company’s stock after buying an additional 5,180 shares during the quarter. Aptus Capital Advisors LLC’s holdings in Eli Lilly and Company were worth $31,430,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently bought and sold shares of LLY. Cumberland Partners Ltd boosted its position in shares of Eli Lilly and Company by 173.4% during the 3rd quarter. Cumberland Partners Ltd now owns 21,984 shares of the company’s stock valued at $19,477,000 after acquiring an additional 13,942 shares in the last quarter. Aigen Investment Management LP bought a new position in Eli Lilly and Company in the 3rd quarter valued at $1,433,000. Prime Capital Investment Advisors LLC raised its holdings in shares of Eli Lilly and Company by 2.6% in the third quarter. Prime Capital Investment Advisors LLC now owns 64,372 shares of the company’s stock valued at $57,030,000 after buying an additional 1,635 shares during the last quarter. Total Investment Management Inc. raised its stake in shares of Eli Lilly and Company by 10.1% in the third quarter. Total Investment Management Inc. now owns 261 shares of the company’s stock worth $231,000 after acquiring an additional 24 shares during the last quarter. Finally, Savvy Advisors Inc. lifted its holdings in Eli Lilly and Company by 4.9% during the 3rd quarter. Savvy Advisors Inc. now owns 1,892 shares of the company’s stock worth $1,676,000 after buying an additional 88 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 900 shares of the firm’s stock in a transaction on Friday, November 8th. The stock was sold at an average price of $803.38, for a total value of $723,042.00. Following the completion of the sale, the chief accounting officer now directly owns 5,480 shares of the company’s stock, valued at $4,402,522.40. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders own 0.13% of the company’s stock.

Analyst Ratings Changes

LLY has been the subject of several recent research reports. Sanford C. Bernstein initiated coverage on Eli Lilly and Company in a report on Thursday, October 17th. They set an “outperform” rating and a $1,100.00 price objective for the company. Redburn Atlantic upgraded Eli Lilly and Company to a “hold” rating in a report on Monday, November 4th. Evercore ISI raised shares of Eli Lilly and Company to a “hold” rating in a research report on Thursday, September 5th. Wells Fargo & Company increased their price target on Eli Lilly and Company from $875.00 to $1,000.00 and gave the company an “overweight” rating in a research report on Friday, August 9th. Finally, Guggenheim boosted their target price on shares of Eli Lilly and Company from $884.00 to $1,030.00 and gave the stock a “buy” rating in a report on Friday, August 16th. Four investment analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $1,008.41.

Eli Lilly and Company Stock Down 2.1 %

Eli Lilly and Company stock traded down $17.74 during midday trading on Tuesday, hitting $814.70. 805,882 shares of the stock were exchanged, compared to its average volume of 3,103,661. Eli Lilly and Company has a 52-week low of $561.65 and a 52-week high of $972.53. The company has a quick ratio of 0.97, a current ratio of 1.27 and a debt-to-equity ratio of 2.03. The business’s 50-day moving average price is $893.78 and its 200-day moving average price is $870.11. The stock has a market capitalization of $773.41 billion, a price-to-earnings ratio of 88.08, a price-to-earnings-growth ratio of 3.15 and a beta of 0.43.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share for the quarter, missing analysts’ consensus estimates of $1.52 by ($0.34). The business had revenue of $11.44 billion during the quarter, compared to analysts’ expectations of $12.09 billion. Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. Eli Lilly and Company’s quarterly revenue was up 20.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.10 EPS. On average, research analysts expect that Eli Lilly and Company will post 13.21 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be issued a dividend of $1.30 per share. The ex-dividend date is Friday, November 15th. This represents a $5.20 dividend on an annualized basis and a yield of 0.64%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 56.22%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.